Kimberly J Popovits
CIK 1333482 · Interim CEO · last filed 2026-06-22
Kimberly J Popovits is an Interim CEO who has filed 150 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for KARD, was dated Jun 22, 2026. Across all open-market trades the lifetime net is −$41.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.38M
9
150
-$41.66M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KARD | Director | 20,706 | — | — | $0 | 1 | 2026-06-22 |
| TXG | Director | 37,445 | $58.48 | $2.19M | $0 | 8 | 2026-06-08 |
| KNSA | Director | 15,345 | $77.80 | $1.19M | $0 | 10 | 2026-06-02 |
| RYTM | Director | — | $112.84 | — | $0 | 1 | 2026-04-03 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 9,656 | $104.91 | $1.01M | $0 | 3 | 2026-03-23 |
| Talis Biomedical Corp (TLIS) Delisted | Interim CEO | 7,855 | $2.84 | $22.3K | $84.8K | 4 | 2023-06-12 |
| MyoKardia, Inc. (MYOK) Delisted | Director | 2,300 | — | — | $0 | 7 | 2020-06-23 |
| GENOMIC HEALTH INC (GHDX) Delisted | President and CEO | 104,436 | — | — | -$41.74M | 109 | 2019-10-09 |
| ZS Pharma, Inc. (ZSPH) Delisted | Director | — | — | — | $0 | 1 | 2015-06-25 |
Recent Filings
150 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | KARD | Grant (A) | +20,706 | $0 | EDGAR |
| 2026-06-08 | TXG | Grant (A) | +8,829 | $0 | EDGAR |
| 2026-06-02 | KNSA | Mixed | +2,799 | $0 | EDGAR |
| 2026-04-03 | RYTM | Grant (A) | — | $0 | EDGAR |
| 2026-03-23 | EXACT SCIENCES CORP (EXAS) Delisted | Disp (D) | −16,381 | $0 | EDGAR |
| 2025-08-01 | KNSA | Exer (M) | — | -$1.16M | EDGAR |
| 2025-07-30 | KNSA | Notice (144) | −64,508 | -$1.93M | EDGAR |
| 2025-06-16 | EXACT SCIENCES CORP (EXAS) Delisted | Grant (A) | +9,994 | $0 | EDGAR |
| 2025-06-05 | TXG | Grant (A) | +15,357 | $0 | EDGAR |
| 2025-06-05 | KNSA | Mixed | +3,173 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.